Overactive Bladder Treatment Market Size, Growth by Drug type (Anticholinergic (Solifenacin, Oxybutynin, Tolterodine, Darifenacin), Mirabegron), Botox, Neuromodulation, Disease Type (Idopathic OAB and Neurogenic OAB) & Region - Global Forecasts to 2027
Updated on : March 13, 2023
The global overactive bladder treatment market in terms of revenue was estimated to be worth $3.5 billion in 2022 and is poised to reach $4.2 billion by 2027, growing at a CAGR of 3.6% from 2022 to 2027. Increasing number of patients with overactive bladder, adequate reimbursement policies for the treatment option available are some of the major factors upsurging the market growth. Additionally, increased investment in development of novel drugs and devices is furthermore expected to drive the growth of market. However, product recalls and social stigma are some of the major reasons anticipated to restrict market growth.
To know about the assumptions considered for the study, Request for Free Sample Report
Overactive Bladder Treatment Market Dynamics
DRIVERS: Growing R&D investments and the launch of novel therapies in the coming years
At present, biopharmaceutical and pharmaceutical companies are investing in innovative therapies for overactive bladder treatment, which are expected to be launched during the forecast period. For instance, Taiho Pharmaceutical is developing TAC-302, a drug currently in Phase II development. This is an orally bioavailable drug that can be used to treat overactive bladder by stimulating neurite outgrowth activity in cultured peripheral neurons. The launch of novel treatment options will increase the adoption of treatment subsequently driving the growth of market.
RESTRAINTS: Frequent product recalls
Overactive bladder is a chronic medical condition that impacts the quality of life of a significant amount of the population. Frequent recalls of drugs used for treating OAB may limit market growth in the coming years. In June 2021, Cipla recalled 7,228 bottles of Solifenacin Succinate tablets in the US due to manufacturing issues. Such frequent recalls by leading pharmaceutical companies impede the growth of the market.
OPPORTUNITIES: Novel treatments, robust pipelines, and patent cliff of certain drugs
There are currently more than 30 candidates for OAB in clinical trial pipelines. Of these, three are in Phase II, seven in Phase III, and sixteen in Phase IV. This robust pipeline and the subsequent launch of newer drugs and therapies in the market are expected to drive the market for overactive bladder treatment. Samsung Medical Center is studying potential biomarkers such as Nerve Growth Factor (NGF), prostaglandin E2 (PGE2), and adenosine triphosphate (ATP) in OAB patients and the effect of these drugs on them. This will assist in predicting treatment responsiveness to provide individualized treatments. Such developments are expected to provide considerable growth opportunities for players in the OAB treatment market.
Mirabergon dominant the type segment in overactive bladder treatment market
Based on type, the market is segmented into anticholinergics, mirabegron, BOTOX, neuromodulation, and other treatments. Mirabegron held a dominant share of the market in 2021, owing factors such as fewer side-effects & less risk of dementia. The neuromodulation segment is anticipated to grow at significant CAGR owing to increased adoption and investment by market players for launch of novel SNM & PTNS devices.
The idiopathic overactive bladder dominated the overactive bladder treatment market in 2021
Based on disease type, the market is segmented into idiopathic and neurogenic overactive bladder syndromes. The idiopathic overactive bladder syndrome segment accounted for a larger market share due to the higher prevalence of idiopathic overactive bladder disorders. Furthermore, increased use of SNM therapy for the patients with idiopathic overactive bladder is anticipated to contribute towards the segmental growth.
North America accounted for largest share in overactive bladder treatment market in 2021
Geographically, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America held dominant share followed by Europe. The dominance of the region is attributable to the various factors such as increased incidence of patients with overactive bladder in US, favorable reimbursement policies for the treatment options. Additionally, preference of companies operating in the market coupled with ANDA and FDA approval for the various treatment is upsurging the growth of market in the region.
To know about the assumptions considered for the study, download the pdf brochure
Key players in the global overactive bladder treatment (OAB) market include Astellas Pharma Inc. (Japan), Teva Pharmaceutical Industries Ltd. (Israel), Pfizer Inc. (US), Medtronic Plc (Ireland), AbbVie Inc. (US), Viatris Inc. (US), Hisamitsu Pharmaceutical Co., Inc. (Japan), Johnson & Johnson Services, Inc. (US), Endo Pharmaceuticals Inc. (Ireland) and among others
Overactive Bladder Treatment Market Report Scope:
|
Report Metrics |
Details |
|
Market Size value 2027 |
USD 4.2 billion |
|
Growth Rate |
3.6% CAGR |
|
Largest Market |
North America |
|
Market Dynamics |
Drivers, Opportunities, Restraints & Challenges |
|
Largest Share Segments |
Type - Mirabergon, Disease Type - The idiopathic overactive bladder |
|
Forecasts up to |
2027 |
|
Market Segmentation |
Type, Disease Type And Regional Level |
|
Growth Drivers |
Growing R&D investments and the launch of novel therapies in the coming years |
|
Growth Opportunities |
Novel treatments, robust pipelines, and patent cliff of certain drugs |
|
Geographies Covered |
North America, Europe, APAC, MEA, and Latin America |
This report categorizes the overactive bladder treatment market into the following segments & sub-segments:
By Type
- Anticholinergics
- Mirabegron
- BOTOX
- Neuromodulation
- Other Treatments.
By Disease Type
- Idiopathic Overactive Bladder
- Neurogenic Overactive Bladder
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Europe
-
Asia Pacific
- China
- Japan
- India
- Australia
- Rest of Asia Pacific
-
Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
Recent Developments
- In March 2021, Myrbetriq received the U.S. Food and Drug Administration approval to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older.
- In December 2020, FDA approved GEMTESA (Vibegron) for the treatment of adults with overactive bladder (OAB). Vibegron is a small molecule, selective human beta-3 adrenergic agonist developed by Urovant Sciences, a subsidiary of Sumitovant Biopharma
Frequently Asked Questions (FAQ):
What is the projected market value of the global overactive bladder treatment market?
The global market of overactive bladder treatment is projected to reach USD 4.2 billion.
What is the estimated growth rate (CAGR) of the global overactive bladder treatment market for the next five years?
The global overactive bladder treatment market is projected to grow at a Compound Annual Growth Rate (CAGR) of 3.6% from 2022 to 2027.
What are the major revenue pockets in the overactive bladder treatment market currently?
Geographically, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America held dominant share followed by Europe. The dominance of the region is attributable to the various factors such as increased incidence of patients with overactive bladder in US, favorable reimbursement policies for the treatment options. Additionally, preference of companies operating in the market coupled with ANDA and FDA approval for the various treatment is upsurging the growth of market in the region.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 28)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 33)
2.1 RESEARCH APPROACH
FIGURE 1 RESEARCH DESIGN
2.1.1 PRIMARY RESEARCH
FIGURE 2 OVERACTIVE BLADDER TREATMENT MARKET: PRIMARY RESPONDENTS
2.1.2 TOP-DOWN AND BOTTOM-UP APPROACHES
FIGURE 3 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE-BASED ESTIMATION
2.2 DATA TRIANGULATION APPROACH
FIGURE 5 DATA TRIANGULATION METHODOLOGY
2.2.1 SECONDARY RESEARCH
2.2.2 COVID-19-SPECIFIC ASSUMPTIONS
2.3 RESEARCH LIMITATIONS
2.4 RISK ASSESSMENT
2.5 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
2.5.1 SUPPLY SIDE
2.5.2 DEMAND SIDE
2.5.2.1 Insights from primary experts
3 EXECUTIVE SUMMARY (Page No. - 41)
FIGURE 6 MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 7 MARKET, BY DISEASE TYPE 2022 VS. 2027 (USD MILLION)
FIGURE 8 GEOGRAPHICAL SNAPSHOT OF THE MARKET
4 PREMIUM INSIGHTS (Page No. - 44)
4.1 OVERACTIVE BLADDER TREATMENT MARKET OVERVIEW
FIGURE 9 RISING PREVALENCE OF OVERACTIVE BLADDER SYNDROME AND FAVORABLE REIMBURSEMENT POLICIES ARE KEY FACTORS DRIVING MARKET GROWTH
4.2 ASIA PACIFIC: MARKET SHARE, BY TYPE AND COUNTRY (2021)
FIGURE 10 MIRABEGRON ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2021
4.3 MARKET SHARE, BY DISEASE TYPE, 2022 VS. 2027
FIGURE 11 IDIOPATHIC OVERACTIVE BLADDER SYNDROME SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2027
4.4 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 12 US TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 48)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 13 MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 1 MARKET: IMPACT ANALYSIS
5.2.1 MARKET DRIVERS
5.2.1.1 Rising prevalence of overactive bladder syndrome
5.2.1.2 Rapidly aging population and subsequent rise in incidence of diseases characterized by OAB
FIGURE 14 PROJECTED GROWTH IN THE ELDERLY POPULATION ABOVE 60, 2015 VS. 2030 VS. 2050
5.2.1.3 Development and use of innovative intravesical therapies
5.2.1.4 Growing R&D investments and the launch of novel therapies in the coming years
5.2.2 MARKET RESTRAINTS
5.2.2.1 Frequent product recalls
5.2.2.2 Increased side effects of anticholinergic drugs
5.2.3 MARKET OPPORTUNITIES
5.2.3.1 Novel treatments, robust pipelines, and patent cliff of certain drugs
5.2.4 MARKET CHALLENGES
5.2.4.1 Social stigma and lack of awareness about OAB
5.3 IMPACT OF UNCERTAINTIES ON THE MARKET
FIGURE 15 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE MARKET
5.4 IMPACT OF COVID-19 ON THE MARKET
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 16 REVENUE SHIFT AND NEW POCKETS FOR THE MARKET
5.6 VALUE CHAIN ANALYSIS
FIGURE 17 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE
5.7 SUPPLY CHAIN ANALYSIS
FIGURE 18 DIRECT DISTRIBUTION—THE PREFERRED STRATEGY OF PROMINENT COMPANIES
5.8 ECOSYSTEM ANALYSIS
FIGURE 19 ECOSYSTEM ANALYSIS OF THE PHARMACEUTICAL INDUSTRY
FIGURE 20 ECOSYSTEM ANALYSIS OF THE UROLOGY DEVICES INDUSTRY
5.9 REGULATORY SCENARIO
5.9.1 PHARMACEUTICAL INDUSTRY
5.9.1.1 Regulatory requirements
5.9.1.1.1 EU regulations
5.9.1.1.2 US regulations
5.9.2 MEDICAL DEVICE INDUSTRY
5.9.2.1 Regulatory requirements
5.9.2.1.1 EU regulations
5.9.2.1.2 US regulations
TABLE 2 LIST OF REGULATORY AUTHORITIES
5.10 TECHNOLOGY ANALYSIS
5.11 KEY CONFERENCES AND EVENTS IN 2022–2023
TABLE 3 MARKET: LIST OF CONFERENCES AND EVENTS
5.12 PATENT ANALYSIS
FIGURE 21 LIST OF MAJOR PATENTS IN THE MARKET
TABLE 4 OVERVIEW OF PATENTS IN THE MARKET
5.13 PORTER’S FIVE FORCES ANALYSIS
TABLE 5 MARKET: PORTER’S FIVE FORCES ANALYSIS
5.13.1 THREAT FROM NEW ENTRANTS
5.13.2 THREAT FROM SUBSTITUTES
5.13.3 BARGAINING POWER OF BUYERS
5.13.4 BARGAINING POWER OF SUPPLIERS
5.13.5 DEGREE OF COMPETITION
5.14 PRICING ANALYSIS
TABLE 6 COST OF DRUGS USED IN OVERACTIVE BLADDER TREATMENT IN VARIOUS REGIONS (GENERICS)
TABLE 7 COST OF BOTOX AND NEUROMODULATION USED IN OVERACTIVE BLADDER TREATMENT IN VARIOUS REGIONS
TABLE 8 COST OF BRANDED DRUGS USED IN OVERACTIVE BLADDER TREATMENT IN VARIOUS REGIONS
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
FIGURE 22 KEY STAKEHOLDERS IN PHARMACEUTICAL COMPANIES AND THEIR INFLUENCE ON THE BUYING PROCESS
FIGURE 23 KEY BUYING CRITERIA FOR OVERACTIVE BLADDER TREATMENT PRODUCTS AMONG END USERS
5.16 PIPELINE ANALYSIS
FIGURE 24 PIPELINE ANALYSIS: PHASES OF DRUGS IN CLINICAL TRIALS
6 OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE (Page No. - 71)
6.1 INTRODUCTION
TABLE 9 MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 10 MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2 MIRABEGRON
6.2.1 FEWER SIDE EFFECTS COMPARED WITH ANTICHOLINERGICS ARE LIKELY TO PROPEL THE GROWTH OF THIS MARKET SEGMENT
TABLE 11 MARKET FOR MIRABEGRON, BY REGION, 2020–2027 (USD MILLION)
6.3 ANTICHOLINERGICS
TABLE 12 MARKET FOR ANTICHOLINERGICS, BY REGION, 2020–2027 (USD MILLION)
TABLE 13 MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
6.3.1 SOLIFENACIN
6.3.1.1 Solifenacin is more effective than other anticholinergics in reducing the frequency of incontinence—a key factor driving market growth
TABLE 14 MARKET FOR SOLIFENACIN, BY REGION, 2020–2027 (USD MILLION)
6.3.2 OXYBUTYNIN
6.3.2.1 Oxybutynin is the most widely prescribed anticholinergic drug in the OAB market
TABLE 15 MARKET FOR OXYBUTYNIN, BY REGION, 2020–2027 (USD MILLION)
6.3.3 FESOTERODINE
6.3.3.1 Fesoterodine exhibits antimuscarinic effects on the muscarinic acetylcholine receptors in the detrusor muscle, leading to a decrease in bladder contractions
TABLE 16 MARKET FOR FESOTERODINE, BY REGION, 2020–2027 (USD MILLION)
6.3.4 DARIFENACIN
6.3.4.1 Cost of darifenacin is higher than other anticholinergics, which is likely to restrain market growth to a certain extent
TABLE 17 MARKET FOR DARIFENACIN, BY REGION, 2020–2027 (USD MILLION)
6.3.5 TOLTERODINE
6.3.5.1 Tolterodine is the third-most-prescribed drug for OAB as it has fewer side effects and offers long-term clinical efficacy
TABLE 18 MARKET FOR TOLTERODINE, BY REGION, 2020–2027 (USD MILLION)
6.3.6 TROSPIUM
6.3.6.1 Trospium is associated with a lower incidence of dry mouth, as a result of which its discontinuation rate is relatively low
TABLE 19 MARKET FOR TROSPIUM, BY REGION, 2020–2027 (USD MILLION)
6.3.7 OTHER ANTICHOLINERGICS
TABLE 20 MARKET FOR OTHER ANTICHOLINERGICS, BY REGION, 2020–2027 (USD MILLION)
6.4 BOTOX
6.4.1 HIGHER EFFICACY OF BOTOX THAN ANTICHOLINERGICS MAKES IT A POPULAR TREATMENT ALTERNATIVE
TABLE 21 MARKET FOR BOTOX, BY REGION, 2020–2027 (USD MILLION)
6.5 NEUROMODULATION
6.5.1 INCREASING ADOPTION OF NEUROMODULATION FOR OVERACTIVE BLADDER TREATMENT TO DRIVE GROWTH IN THIS MARKET SEGMENT
TABLE 22 MARKET FOR NEUROMODULATION, BY REGION, 2020–2027 (USD MILLION)
6.6 OTHER TREATMENTS
TABLE 23 MARKET FOR OTHER TREATMENTS, BY REGION, 2020–2027 (USD MILLION)
7 OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE (Page No. - 85)
7.1 INTRODUCTION
TABLE 24 MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
7.2 IDIOPATHIC OVERACTIVE BLADDER SYNDROME
7.2.1 AVAILABILITY OF REIMBURSEMENTS FOR DRUGS USED TO TREAT IDIOPATHIC OAB TO FUEL GROWTH IN THIS MARKET
TABLE 25 IDIOPATHIC OVERACTIVE-BLADDER TREATMENT MARKET, BY REGION, 2020–2027 (USD MILLION)
7.3 NEUROGENIC OVERACTIVE BLADDER SYNDROME
TABLE 26 NEUROGENIC OVERACTIVE-BLADDER TREATMENT MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 27 NEUROGENIC OVERACTIVE-BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
7.3.1 PARKINSON'S DISEASE
7.3.1.1 Increased use of anticholinergics and beta-adrenergic agonists for the treatment of Parkinson’s disease to drive market growth
TABLE 28 NEUROGENIC OVERACTIVE-BLADDER TREATMENT MARKET FOR PARKINSON’S DISEASE, BY REGION, 2020–2027 (USD MILLION)
7.3.2 STROKES
7.3.2.1 Rising prevalence of strokes to increase the incidence of OAB and fuel the demand for OAB treatment
TABLE 29 NEUROGENIC OVERACTIVE-BLADDER TREATMENT MARKET FOR STROKES, BY REGION, 2020–2027 (USD MILLION)
7.3.3 MULTIPLE SCLEROSIS
7.3.3.1 Favorable reimbursement policies to support the growth of the OAB treatment market for MS
TABLE 30 NEUROGENIC OVERACTIVE-BLADDER TREATMENT MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2020–2027 (USD MILLION)
7.3.4 SPINAL CORD INJURIES
7.3.4.1 High prevalence of bladder overactivity in SCI contributes to the growth of the neurogenic bladder overactivity treatment market
TABLE 31 NEUROGENIC OVERACTIV-BLADDER TREATMENT MARKET FOR SPINAL CORD INJURIES, BY REGION, 2020–2027 (USD MILLION)
7.3.5 OTHER DISORDERS
TABLE 32 NEUROGENIC OVERACTIVE-BLADDER TREATMENT MARKET FOR OTHER DISORDERS, BY REGION, 2020–2027 (USD MILLION)
8 OVERACTIVE BLADDER TREATMENT MARKET, BY REGION (Page No. - 95)
8.1 INTRODUCTION
TABLE 33 MARKET, BY REGION, 2020–2027 (USD MILLION)
8.2 NORTH AMERICA
FIGURE 25 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET SNAPSHOT
TABLE 34 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 35 NORTH AMERICA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 36 NORTH AMERICA: MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 37 NORTH AMERICA: MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 38 NORTH AMERICA: NEUROGENIC OVERACTIVE-BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.2.1 US
8.2.1.1 Favorable reimbursement policies make the US the largest market for bladder overactivity treatment
TABLE 39 US: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 40 US: MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 41 US: MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 42 US: NEUROGENIC OVERACTIVE-BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.2.2 CANADA
8.2.2.1 Increased use of and demand for BOTOX to treat overactive bladder to drive market growth in Canada
TABLE 43 CANADA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 44 CANADA: MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 45 CANADA: MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 46 CANADA: NEUROGENIC OVERACTIVE-BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3 EUROPE
TABLE 47 EUROPE: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 48 EUROPE: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 49 EUROPE: MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 50 EUROPE: MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 51 EUROPE: NEUROGENIC OVERACTIVE-BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.1 GERMANY
8.3.1.1 Aging population and a high prevalence of OAB, especially in women, are expected to increase target patient groups in Germany
TABLE 52 GERMANY: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 53 GERMANY: MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 54 GERMANY: MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 55 GERMANY: NEUROGENIC OVERACTIVE-BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.2 UK
8.3.2.1 Initiatives and awareness campaigns in the UK to drive growth in the OAB market
TABLE 56 ANNUAL COST OF OVERACTIVE BLADDER TREATMENT IN THE UK
TABLE 57 UK: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 58 UK: MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 59 UK: MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 60 UK: NEUROGENIC OVERACTIVE-BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.3 FRANCE
8.3.3.1 Low reimbursement rate in France compared to other countries may limit market growth to a certain extent
TABLE 61 REIMBURSEMENT RATES FOR OVERACTIVE BLADDER TREATMENT IN FRANCE
TABLE 62 FRANCE: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 63 FRANCE: MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 64 FRANCE: MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 65 FRANCE: NEUROGENIC OVERACTIVE-BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.4 ITALY
8.3.4.1 Italian pharmaceutical industry is expected to offer lucrative growth opportunities to OAB drug manufacturers
TABLE 66 ITALY: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 67 ITALY: OVERACTIVE MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 68 ITALY: MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 69 ITALY: NEUROGENIC OVERACTIVE-BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.5 SPAIN
8.3.5.1 Changing demographics and high OAB prevalence in Spain offer significant growth opportunities for the bladder overactivity treatment market
TABLE 70 SPAIN: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 71 SPAIN: MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 72 SPAIN: MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 73 SPAIN: NEUROGENIC OVERACTIVE-BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.3.6 REST OF EUROPE
TABLE 74 REST OF EUROPE: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 75 REST OF EUROPE: MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 76 REST OF EUROPE: MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 77 REST OF EUROPE: NEUROGENIC BLADDER-TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.4 ASIA PACIFIC
FIGURE 26 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET SNAPSHOT
TABLE 78 ASIA PACIFIC: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 79 ASIA PACIFIC: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 80 ASIA PACIFIC: MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 81 ASIA PACIFIC: MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 82 ASIA PACIFIC: NEUROGENIC OVERACTIVE-BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.4.1 JAPAN
8.4.1.1 Advancements in treatment options to fuel growth in the market in Japan
TABLE 83 JAPAN: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 84 JAPAN: MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 85 JAPAN: MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 86 JAPAN: NEUROGENIC OVERACTIVE-BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.4.2 CHINA
8.4.2.1 Growing adoption of BOTOX for OAB treatment makes China a lucrative market
TABLE 87 CHINA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 88 CHINA: MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 89 CHINA: MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 90 CHINA: NEUROGENIC OVERACTIVE-BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.4.3 INDIA
8.4.3.1 India is the world’s largest producer of generic drugs— a key factor driving market growth
TABLE 91 INDIA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 92 INDIA: MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 93 INDIA: MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 94 INDIA: NEUROGENIC OVERACTIVE-BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.4.4 AUSTRALIA
8.4.4.1 Growing aging population is likely to increase the number of patients suffering from OAB in Australia—a major factor supporting the growth of this market
TABLE 95 AUSTRALIA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 96 AUSTRALIA: MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 97 AUSTRALIA: MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 98 AUSTRALIA: NEUROGENIC OVERACTIVE-BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.4.5 REST OF ASIA PACIFIC
TABLE 99 REST OF ASIA PACIFIC: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 100 REST OF ASIA PACIFIC: MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 101 REST OF ASIA PACIFIC: MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 102 REST OF ASIA PACIFIC: NEUROGENIC OVERACTIVE-BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.5 LATIN AMERICA
TABLE 103 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 104 LATIN AMERICA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 105 LATIN AMERICA: MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 106 LATIN AMERICA: MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 107 LATIN AMERICA: NEUROGENIC OVERACTIVEBLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.5.1 BRAZIL
8.5.1.1 Increased use of overactive bladder drugs in the country to drive growth in the market
FIGURE 27 DISTRIBUTION OF POPULATION IN BRAZIL (ABOVE-60 AGE GROUP), 2004–2050
TABLE 108 BRAZIL: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 109 BRAZIL: MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 110 BRAZIL: MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 111 BRAZIL: NEUROGENIC OVERACTIVE-BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.5.2 MEXICO
8.5.2.1 Rising prevalence of OAB to drive growth in the market in Mexico
TABLE 112 MEXICO: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 113 MEXICO: MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 114 MEXICO: MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 115 MEXICO: NEUROGENIC OVERACTIVE-BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.5.3 REST OF LATIN AMERICA
TABLE 116 REST OF LATIN AMERICA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 117 REST OF LATIN AMERICA: MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 118 REST OF LATIN AMERICA: MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 119 REST OF LATIN AMERICA: NEUROGENIC OVERACTIVE-BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
8.6 MIDDLE EAST & AFRICA
8.6.1 RISING AWARENESS OF OAB IS LIKELY TO DRIVE THE GROWTH OF THE MARKET IN THE MIDDLE EAST & AFRICA
TABLE 120 MIDDLE EAST & AFRICA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 121 MIDDLE EAST & AFRICA: MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 122 MIDDLE EAST & AFRICA: MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 123 MIDDLE EAST & AFRICA: NEUROGENIC OVERACTIVE-BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
9 COMPETITIVE LANDSCAPE (Page No. - 149)
9.1 INTRODUCTION
9.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
FIGURE 28 OVERACTIVE BLADDER TREATMENT MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
9.3 MARKET SHARE ANALYSIS
FIGURE 29 MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2021)
TABLE 124 MARKET: DEGREE OF COMPETITION
9.4 REVENUE ANALYSIS
FIGURE 30 REVENUE ANALYSIS FOR KEY COMPANIES (2019–2021)
9.5 COMPANY EVALUATION QUADRANT
9.5.1 STARS
9.5.2 EMERGING LEADERS
9.5.3 PERVASIVE PLAYERS
9.5.4 PARTICIPANTS
FIGURE 31 MARKET: COMPANY EVALUATION MATRIX, 2021
9.6 COMPETITIVE BENCHMARKING OF TOP 20 PLAYERS
9.6.1 COMPANY FOOTPRINT (20 COMPANIES)
TABLE 125 COMPANY FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE MARKET
9.6.2 COMPANY PRODUCT FOOTPRINT (20 COMPANIES)
TABLE 126 PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE MARKET
9.6.3 COMPANY REGIONAL FOOTPRINT (20 COMPANIES)
TABLE 127 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE MARKET
9.7 COMPANY EVALUATION QUADRANT: START-UPS/SMES
9.7.1 PROGRESSIVE COMPANIES
9.7.2 STARTING BLOCKS
9.7.3 RESPONSIVE COMPANIES
9.7.4 DYNAMIC COMPANIES
FIGURE 32 MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021
9.7.5 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
TABLE 128 MARKET: DETAILED LIST OF KEY START-UPS/SMES
TABLE 129 MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (START-UPS/SMES)
9.8 COMPETITIVE SCENARIO AND TRENDS
9.8.1 PRODUCT LAUNCHES & APPROVALS
TABLE 130 PRODUCT LAUNCHES & APPROVALS, JANUARY 2019–MAY 2022
9.8.2 DEALS
TABLE 131 DEALS, JANUARY 2019–MAY 2022
10 COMPANY PROFILES (Page No. - 163)
10.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1.1 ASTELLAS PHARMA INC.
TABLE 132 ASTELLAS PHARMA INC.: BUSINESS OVERVIEW
FIGURE 33 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2021)
10.1.2 TEVA PHARMACEUTICAL INDUSTRIES LTD.
TABLE 133 TEVA PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW
FIGURE 34 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2021)
10.1.3 PFIZER INC.
TABLE 134 PFIZER INC.: BUSINESS OVERVIEW
FIGURE 35 PFIZER INC.: COMPANY SNAPSHOT (2021)
10.1.4 ABBVIE INC.
TABLE 135 ABBVIE INC.: BUSINESS OVERVIEW
FIGURE 36 ABBVIE INC.: COMPANY SNAPSHOT (2021)
10.1.5 VIATRIS INC.
TABLE 136 VIATRIS INC.: BUSINESS OVERVIEW
FIGURE 37 VIATRIS INC.: COMPANY SNAPSHOT (2021)
10.1.6 HISAMITSU PHARMACEUTICAL CO., INC.
TABLE 137 HISAMITSU PHARMACEUTICAL CO., INC.: BUSINESS OVERVIEW
FIGURE 38 HISAMITSU PHARMACEUTICAL CO., INC.: COMPANY SNAPSHOT (2020)
10.1.7 JOHNSON & JOHNSON SERVICES, INC.
TABLE 138 JOHNSON & JOHNSON SERVICES, INC.: BUSINESS OVERVIEW
FIGURE 39 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2021)
10.1.8 ENDO PHARMACEUTICALS INC.
TABLE 139 ENDO PHARMACEUTICALS INC.: BUSINESS OVERVIEW
FIGURE 40 ENDO PHARMACEUTICALS INC.: COMPANY SNAPSHOT
10.1.9 LUPIN
TABLE 140 LUPIN: BUSINESS OVERVIEW
FIGURE 41 LUPIN: COMPANY SNAPSHOT (2021)
10.1.10 AMNEAL PHARMACEUTICALS LLC
TABLE 141 AMNEAL PHARMACEUTICALS LLC: BUSINESS OVERVIEW
FIGURE 42 AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT (2021)
10.1.11 SUN PHARMACEUTICAL INDUSTRIES LTD.
TABLE 142 SUN PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW
FIGURE 43 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2021)
10.1.12 GLENMARK
TABLE 143 GLENMARK: BUSINESS OVERVIEW
FIGURE 44 GLENMARK: COMPANY SNAPSHOT (2021)
10.1.13 MACLEODS PHARMACEUTICALS LTD.
TABLE 144 MACLEODS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
FIGURE 45 MACLEODS PHARMACEUTICALS LTD.: COMPANY SNAPSHOT (2021)
10.1.14 MEDTRONIC
TABLE 145 MEDTRONIC: BUSINESS OVERVIEW
FIGURE 46 MEDTRONIC: COMPANY SNAPSHOT (2021)
10.1.15 AJANTA PHARMA
TABLE 146 AJANTA PHARMA: BUSINESS OVERVIEW
FIGURE 47 AJANTA PHARMA: COMPANY SNAPSHOT (2021)
10.1.16 GRANULES INDIA LIMITED
TABLE 147 GRANULES INDIA LIMITED: BUSINESS OVERVIEW
FIGURE 48 GRANULES INDIA LIMITED: COMPANY SNAPSHOT (2021)
10.2 OTHER PLAYERS
10.2.1 UROVANT SCIENCES
TABLE 148 UROVANT SCIENCES: BUSINESS OVERVIEW
10.2.2 APOTEX INC.
TABLE 149 APOTEX INC.: BUSINESS OVERVIEW
10.2.3 LABORIE
TABLE 150 LABORIE: BUSINESS OVERVIEW
10.2.4 INTAS PHARMACEUTICALS LTD.
TABLE 151 INTAS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
10.2.5 BAYER AG
TABLE 152 BAYER AG: BUSINESS OVERVIEW
10.2.6 MEDYTOX
TABLE 153 MEDYTOX: BUSINESS OVERVIEW
10.2.7 ALTHERX PHARMACEUTICALS
TABLE 154 ALTHERX PHARMACEUTICALS: BUSINESS OVERVIEW
10.2.8 TAIHO PHARMACEUTICAL CO., LTD.
TABLE 155 TAIHO PHARMACEUTICAL CO., LTD.: BUSINESS OVERVIEW
10.2.9 HUGEL, INC.
TABLE 156 HUGEL, INC.: BUSINESS OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
11 APPENDIX (Page No. - 203)
11.1 DISCUSSION GUIDE
11.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.3 AVAILABLE CUSTOMIZATIONS
11.4 RELATED REPORTS
11.5 AUTHOR DETAILS
This study involved four major activities in estimating the current size of the overactive bladder treatment market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the overactive bladder treatment market. The secondary sources used for this study include American Urological Association (AUA), National Center for Biotechnology Information (NCBI), National Library of Medicine (NLM), European Association of Urology (EAU), Bladder Health UK, Urology Care Foundation (UCF), National Association for Continence (NAFC), National Institutes of Health (NIH), Pharmaceutical Research and Manufacturers of America (PhRMA), Centers for Disease Control and Prevention (CDC), US Food and Drug Administration (FDA), European Medicines Agency (EMA), Lens.org., ClinicalTrials.gov, PubMed, Annual Reports, SEC Filings, Medicaid, Expert Interviews and MarketsandMarkets Analysis, among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the overactive bladder treatment market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and market have been identified through extensive secondary research
- The revenues generated from the overactive bladder treatment business of leading players have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Data Triangulation
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, and forecast the global overactive bladde (OAB) treatment market based on the type, disease type and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, and opportunities)
- To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall overactive bladde (OAB) treatment market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
- To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the overactive bladder treatment(OAB) market.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Growth opportunities and latent adjacency in Overactive Bladder Treatment Market